Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (839) Crestor (rosuvastatin calcium), AstraZeneca,
...Newly Approved Drug Therapies (839) Crestor (rosuvastatin calcium), AstraZeneca, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Crestor (rosuvastatin calcium) Company: AstraZeneca Approval Status: Approved August 2003 Treatment Area: Hypercholesterolemia General Information Crestor (rosuvastatin calcium ...
View Page

2.  Newly Approved Drug Therapies (844) Lexiva (fosamprenavir calcium), GlaxoSmithKline,
...Newly Approved Drug Therapies (844) Lexiva (fosamprenavir calcium), GlaxoSmithKline, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Lexiva (fosamprenavir calcium) Company: GlaxoSmithKline Approval Status: Approved October 2003 Treatment Area: HIV Infection General Information Lexiva (formerly ...
View Page

3.  Newly Approved Drug Therapies (866) Campral (acamprosate calcium), Forest Laboratories,
...Newly Approved Drug Therapies (866) Campral (acamprosate calcium), Forest Laboratories, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Campral (acamprosate calcium) Company: Forest Laboratories Approval Status: Approved August, 2004 Treatment Area: Alcohol dependence General Information Campral ...
View Page

4.  Newly Approved Drug Therapies (94) Bactroban Nasal 2% (mupirocin calcium ointment), SmithKline Beecham,
...Newly Approved Drug Therapies (94) Bactroban Nasal 2% (mupirocin calcium ointment), SmithKline Beecham, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Bactroban Nasal 2% (mupirocin calcium ointment) Company: SmithKline Beecham Approval Status: Approved April 1996 Treatment Area: nasal bacteria General Information ...
View Page

5.  CenterWatch: New Medical Therapies in Disease Category (116), Parathyroid Disorders
...December 1, 2003 Amgen reported positive results from a phase III trial investigating cinacalcet , a calcium-sensing receptor modulator for the treatment of hyperparathyroidism (HPT). Results showed a 13 to 17 % reduction in calcium-phosphorus product, a 6-8% reduction in calcium and a 7-10% reduction in phosphorus ...
View Page

6.  CenterWatch: New Medical Therapies in Disease Category (266), Parathyroid Disease
...December 1, 2003 Amgen reported positive results from a phase III trial investigating cinacalcet , a calcium-sensing receptor modulator for the treatment of hyperparathyroidism (HPT). Results showed a 13 to 17 % reduction in calcium-phosphorus product, a 6-8% reduction in calcium and a 7-10% reduction in phosphorus ...
View Page

7.  Study Posting (5316) Trial #151343, Osteoporosis, Gainesville, FL
...Osteoporosis, Gainesville, FL Trial Information Phase 1 study to assess the effect breakfast, dinner and Calcium/Vitamin D tablets have on an investigational formulation of an osteoporosis drug The University of ...
...Trials Research is conducting a clinical research study to assess the effect breakfast, dinner and Calcium /Vitamin D tablets have on an investigational formulation of an osteoporosis drug. Your participation will ...
View Page

8.  Study Posting (5316) Trial #151344, Women's Health, Gainesville, FL
...Health, Gainesville, FL Trial Information Phase 1 study to assess the effect breakfast, dinner and Calcium/Vitamin D tablets have on an investigational formulation of an osteoporosis drug The University of ...
...Trials Research is conducting a clinical research study to assess the effect breakfast, dinner and Calcium /Vitamin D tablets have on an investigational formulation of an osteoporosis drug. Your participation will ...
View Page

9.  Newly Approved Drug Therapies (852) Sensipar (cinacalcet), Amgen,
...Sensipar is an oral calcimimetic medication that lowers the levels of parathyroid hormone, phosphurous and calcium in patients undergoing kidney dialysis or in patients with parathroid cancer. Sensipar is indicated for ...
...of secondary hyperparathyroidism in chronic kidney disease patients on dialysis and the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma. The recommended starting oral dose of Sensipar is ...
View Page

10.  Study Posting (5031) Trial #152702, Bone Diseases, Various Cities, WI
...find out if educating study investigators and participants effect of investigator and patient education on calcium and vitamin D supplementation can manage the potential for hypocalcemia (calcium deficiency) following the administration of a study drug injection in participants with Paget's disease ...
View Page

11.  Study Posting (5031) Trial #152701, Bone Diseases, Various Cities, TX
...find out if educating study investigators and participants effect of investigator and patient education on calcium and vitamin D supplementation can manage the potential for hypocalcemia (calcium deficiency) following the administration of a study drug injection in participants with Paget's disease ...
View Page

12.  Study Posting (5031) Trial #152700, Bone Diseases, Various Cities, RI
...find out if educating study investigators and participants effect of investigator and patient education on calcium and vitamin D supplementation can manage the potential for hypocalcemia (calcium deficiency) following the administration of a study drug injection in participants with Paget's disease ...
View Page

13.  Study Posting (5031) Trial #152698, Bone Diseases, Various Cities, GA
...find out if educating study investigators and participants effect of investigator and patient education on calcium and vitamin D supplementation can manage the potential for hypocalcemia (calcium deficiency) following the administration of a study drug injection in participants with Paget's disease ...
View Page

14.  Study Posting (5031) Trial #152697, Bone Diseases, Various Cities, CO
...find out if educating study investigators and participants effect of investigator and patient education on calcium and vitamin D supplementation can manage the potential for hypocalcemia (calcium deficiency) following the administration of a study drug injection in participants with Paget's disease ...
View Page

15.  Study Posting (5031) Trial #152696, Bone Diseases, Various Cities, CA
...find out if educating study investigators and participants effect of investigator and patient education on calcium and vitamin D supplementation can manage the potential for hypocalcemia (calcium deficiency) following the administration of a study drug injection in participants with Paget's disease ...
View Page

16.  Newly Approved Drug Therapies (274) Posicor, Roche,
...June 1997 Treatment Area: hypertension and chronic stable angina pectoris General Information Posicor (mibefradil), a calcium channel blocker, will be available in 50 mg and 100 mg tablets for treatment of ...
...when used in conjunction with agents metabolized by P450. Mechanism of Action Mibefradil, a subtype calcium channel blocker, blocks both low and high voltage calcium channels with greater selectivity for low ...
View Page

17.  Newly Approved Drug Therapies (721) Zometa (zoledronic acid), Novartis,
...over-stimulation results in an increased rate of bone breakdown and the release of excess calcium into the bloodstream. The kidneys are unable to cope with the excessively high calcium levels and the calcium remains in the blood, leading to complications such as dehydration, fatigue ...
View Page

18.  Study Posting (168) Trial #75328, Renal Artery Disease, Hollywood, FL
...Patients currently on dialysis A Prospective, Multicenter, Randomized, Open Label, Parallel Arm, Comparison Study of Calcium Acetate + Atorvastatin and Sevelamer +/- Atorvastatin on Cardiovascular Calcification and Phosphorus Levels in Patients with End ...
View Page

19.  Study Posting (77) Trial #136057, Kidney Disease, Great Neck, NY
...is being done to evaluate the safety and effects of the combination of Crestor® (rosuvastatin calcium) and a experimental drug on people with stage 3 chronic kidney disease and Dyslipidemia (a ...
View Page

20.  Study Posting (77) Trial #134915, Kidney Disease, Lake Success, NY
...is being done to evaluate the safety and effects of the combination of Crestor® (rosuvastatin calcium) and a experimental drug on people with stage 3 chronic kidney disease and Dyslipidemia (a ...
View Page